Logo image
Back
The terminal cancer patient: effects of age, gender, and primary tumor site on opioid dose
Journal article   Open access   Peer reviewed

The terminal cancer patient: effects of age, gender, and primary tumor site on opioid dose

Susannah Hall, Rollin M Gallagher, Edward Gracely, Calvin Knowlton and Douglas Wescules
Pain medicine (Malden, Mass.), v 4(2), pp 125-134
Jun 2003
DOI: https://doi.org/10.1046/j.1526-4637.2003.03020.x
PMID: 12873262
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1046/j.1526-4637.2003.03020.xView
Published, Version of Record (VoR) Open

Abstract

Oxycodone - therapeutic use Age Factors Fentanyl - therapeutic use Humans Middle Aged Analgesics, Opioid - therapeutic use Male Narcotics - therapeutic use Dose-Response Relationship, Drug Neoplasms - complications Pain - drug therapy Sex Factors Pain - etiology Female Aged Retrospective Studies Morphine - therapeutic use Terminal Care - methods
The objective of the current study is to describe correlations between age, gender, and primary cancer site and sustained-release opioid doses prescribed for hospice patients at the end of life. This study included all 7,201 hospice patients referred to a North American palliative care specialty pharmacy with the primary diagnosis of cancer and who were prescribed transdermal fentanyl, sustained-release oral morphine, or sustained-release oxycodone. This is a retrospective analysis of the final sustained-release morphine, oxycodone, or transdermal fentanyl doses prescribed to cancer patients, according to pharmacy records. Comparisons between sex and age group were performed with chi-square tests. Mann-Whitney U tests were used to compare mean doses between the sexes. Analyses of covariance (ANCOVA) were used to compare opioid doses between genders and among primary cancer sites while controlling for age. The inverse association between age group and dose was highly significant. For example, final opioid doses </=120 mg/day oral morphine equivalent were prescribed for only 46.4% of patients between 40 and 49 years of age compared with 86.4% of patients 90 years of age and older. An ANCOVA on the largest non-sex-related diagnoses found primary tumor site and patient age, but not gender, to be associated with sustained-release opioid dose. Both primary tumor site and patient age were associated with final opioid dose. Further investigation is warranted to determine which primary tumor sites are associated with unusually high opioid doses and may highlight the need to optimize adjuvant medication therapy if neuropathic and/or inflammatory pain mechanisms are involved and to refer to pain specialists when appropriate.

Metrics

12 Record Views
59 citations in Web of Science
70 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Anesthesiology
Logo image